

| Bronson Healthcare | | 2019-20 (two year) Antibiotic Activity Summary | | | | | | | | | | | | | | |
|--|------------|---|-------------------------|--|-------------|----------------|--------------------|--|--------------|------------|--------------|-------------|--------------|--------------------|----------------|--------------|
| | | Antibiogram | | | | | | | | | | | | | | |
| | | Bronson Battle Creek Inpatient, including Select Specialty Hospital | | | | | | | | | | | | | | |
| | | Percent of strains susceptible: | | | | | | | | | | | | | | |
| Gram Negative Enteric Bacteria | No. Tested | Ampicillin/Sulbactam | Piperacillin/tazobactam | Aztreonam | Cefazolin | Cefoxitin | Ceftriaxone | Cefepime | Meropenem | Gentamicin | Tobramycin | Amikacin | Levofloxacin | Sulfa/Trimethoprim | Nitrofurantoin | Tetracycline |
| <i>Enterobacter cloacae</i> | 58 | R | 74 | 76 | R | R | 67 | 97 | 98 | 100 | 100 | 100 | 97 | 90 | 41 | 95 |
| <i>Escherichia coli</i> | 275 | 65 | 94 | 89 | 86 | 88 | 88 | 89 | 100 | 90 | 91 | 100 | 79 | 77 | 96 | 82 |
| <i>Klebsiella oxytoca</i> | 34 | 62 | 91 | 94 | 74 | 100 | 94 | 97 | 100 | 97 | 97 | 100 | 100 | 97 | 76 | 100 |
| <i>Klebsiella pneumoniae</i> | 88 | 72 | 89 | 86 | 82 | 90 | 86 | 86 | 99 | 95 | 95 | 100 | 91 | 81 | 30 | 72 |
| <i>Proteus mirabilis</i> | 65 | 94 | 100 | 94 | 92 | 92 | 94 | 94 | 100 | 89 | 97 | 100 | 66 | 69 | R | R |
| | | | | | | | | | | | | | | | | |
| Gram Negative Non-enteric Bacteria | No. Tested | Piperacillin/tazobactam | Cefepime | Meropenem | Aztreonam | Gentamicin | Tobramycin | Amikacin | Levofloxacin | | | | | | | |
| <i>Pseudomonas aeruginosa</i> | 179 | 91 | 78 | 90 | 78 | 93 | 98 | 98 | 79 | | | | | | | |
| | | | | | | | | | | | | | | | | |
| Enterococci/Streptococci | No. Tested | Penicillin/ampicillin | Levofloxacin | Vancomycin | Linezolid | Nitrofurantoin | Gentamicin Synergy | Streptomycin Synergy | | | | | | | | |
| <i>Enterococcus faecalis</i> | 198 | 100 | 80 | 92 | 100 | 100 | 74 | 78 | | | | | | | | |
| <i>Enterococcus faecium</i> | 40 | R | R | R | 100 | R | 97 | 44 | | | | | | | | |
| <i>Streptococcus agalactiae</i> | 91 | 100 | 96 | 100 | 100 | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| Gram Positive Bacteria | No. Tested | Penicillin/ampicillin | Oxacillin/nafcillin | Erythromycin | Clindamycin | Gentamicin | Levofloxacin | Sulfa/Trimethoprim | Vancomycin | Rifampin* | Tetracycline | Minocycline | Linezolid | Nitrofurantoin | | |
| <i>Staphylococcus aureus</i> | 480 | R | 52 | 36 | 85 | 99 | 64 | 94 | 100 | 100 | 92 | 100 | 100 | 99 | | |
| <i>Staphylococcus epidermidis</i> | 47 | R | R | R | 89 | 85 | 55 | 49 | 100 | 100 | 79 | 100 | 100 | 98 | | |
| R denotes intrinsic resistance | | | | | | | | | | | | | | | | |
| *Rifampin should be used only in combination with another agent | | | | | | | | | | | | | | | | |
| Dosing recommendations are generalized; dosing should be optimized for each patient. | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| Adam Warner, PharmD | | | | Richard Van Enk, Ph.D. | | | | Eric Parnell | | | | | | | | |
| Antimicrobial Stewardship Pharmacist | | | | Epidemiologist | | | | Laboratory Supervisor | | | | | | | | |
| (269) 341-6230 | | | | (269) 341-6316 | | | | (269)341-8845 | | | | | | | | |
| warnera@bronsonhq.org | | | | vanenkr@bronsonhq.org | | | | parnelle@bronsonhq.org | | | | | | | | |